|
Mepolizumab May Substantially Reduce Asthma Exacerbations
JAMA: The Journal of the American Medical Association Mepolizumab, a humanized monoclonal antibody against interleukin-5, significantly reduced asthma exacerbations and improved quality of life among patients treated with inhaled glucocorticoids, according to a randomized, placebo-controlled trial with … |
View full post on asthma – Google News